The price of Karelizumab (200mg/branch) is more than two thousand, and the specific price will be affected by the reimbursement policy of the local health insurance, which will be different.
Karelizumab was approved for marketing in May 2019 for use in patients with classical Hodgkin’s lymphoma, non-squamous non-small cell lung cancer, hepatocellular carcinoma, esophageal squamous carcinoma who meet the conditions of the specification among the patients with the initial price of more than nineteen thousand, but the price was reduced drastically to more than two thousand dollars after entering the health insurance in March 2021, the price of the drug was reduced to more than two thousand dollars.
Karelizumab may have anemia, fatigue, neutropenia, thrombocytopenia, hypothyroidism, autoimmune disease and other adverse reactions, it is prohibited for those who are allergic to it, and the use of children is not clear.
Due to the different reimbursement policies of local health insurance, the specific price will be different, it is recommended to consult the local health insurance department and hospitals. Karelizumab must be applied under the guidance of a doctor, not self-application.